Render Target: STATIC
Render Timestamp:
6/11/2026, 9:31:31 PM EDT
6/12/2026, 1:31:31 AM UTC
Commit: a854f3e2d877b833e27badd637de63a8a4794b83
XML generation date: 2026-04-23 13:33:40.337
Product last modified at: 2026-04-22T08:00:11.072Z
Cell Signaling Technology Logo - Extra Large
1% for the planet logo
PDP - Template Name: Antibody Duet
PDP - Template ID: *******ad0fa02

PhosphoPlus® TGF-beta Receptor I (Ser165) Antibody Duet #92722

    Product Information

    Kit Usage Information

    Protocols

    Product Description

    PhosphoPlus® Duets from Cell Signaling Technology (CST) provide a means to assess protein activation status. Each Duet contains an activation-state and total protein antibody to your target of interest. These antibodies have been selected from CST's product offering based upon superior performance in specified applications.

    Background

    Transforming growth factor-β (TGF-β) proteins belong to the TGF-β superfamily of cytokines that play a critical role in regulating cell proliferation and differentiation, developmental patterning and morphogenesis, and disease pathogenesis (1-3). TGF-β ligands elicit signaling through three cell surface receptors: type I (RI), type II (RII), and type III (RIII) TGF-β receptors. Type I and type II receptors are serine/threonine kinases that form a heteromeric complex following ligand binding to the type II receptor. In response to ligand binding, the type II receptors form a stable complex with the type I receptors, triggering phosphorylation and activation of the type I receptor (4). This results in the recruitment of receptor-mediated SMADs (SMAD2, SMAD3), which are phosphorylated by the type I kinase in an SSXS domain in the C-terminus. This leads to recruitment of the co-SMAD (SMAD4), and subsequent translocation of this heteromeric SMAD complex to the nucleus, where it regulates transcription of target genes (5-7). The type III receptor, also known as betaglycan, is a transmembrane proteoglycan with a large extracellular domain that binds TGF-β with high affinity but lacks a cytoplasmic signaling domain. Expression of the type III receptor can regulate TGF-β signaling through presentation of the ligand to the signaling complex (8).

    Ligand banding and activation of type I receptor phosphorylates the protein at Ser165 and across a glycine, serine, threonine-rich domain (GS domain) at Thr185, Thr186, Ser187, Ser189, and Ser191 (9). Phosphorylation at Ser165 is not critical for transmission of TGF-β signals for transcription, cell growth, or migration, but is required for TGF-β-mediated extracellular matrix (ECM) formation and apoptotic signaling (9). Rottlerin, an activator of Ca2+-activated K+ channels, was shown to suppress TGF-β RI phosphorylation at Ser165 in in vitro and in vivo models of liver fibrosis, resulting in downregulation of pro-fibrotic TGF-β/Smad signaling (10). Overexpression of decorin, an ECM-protective protein, in hepatocullar carcinoma cells increased TGF-β RII expression and TGF-β RI phosphorylation at Ser165, suppressing the proliferation of these cells (11).
    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    PhosphoPlus is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.